clinical trial · NCT07009860
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
Alcohol-associated Liver DiseasePemvidutidePlacebo
brief summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD.
started
Jun 16, 2025
primary completion
Sep 30, 2027
completion
Sep 30, 2027
last updated
Aug 17, 2026
official title
RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol